InvestorsHub Logo
Followers 33
Posts 2666
Boards Moderated 0
Alias Born 10/28/2013

Re: Adam_Feuerstein post# 47854

Sunday, 12/20/2015 9:08:12 PM

Sunday, December 20, 2015 9:08:12 PM

Post# of 742115
""Disbursements" equals cash in Linda Powers' pocket."

This article in the New York times states that it takes about $2.6B to get a drug to market.

http://www.nytimes.com/2014/11/19/upshot/calculating-the-real-costs-of-developing-a-new-drug.html?_r=0

What is Northwests total accumulated shareholder liability? I can't find it quickly. My vague recollection is that the total is about $1B, or less than half the typical cost (according to that recent article).

I would argue that if the total accumulated shareholder liability is smaller than typical then it is not reasonable to damn the company for expenditures. Nobody is happy with the lack of visibility, but they know that Cognate does a great deal for the company. That is why Northwest can get by with so few employees. It would be appropriate if the majority of $ that shareholders have forked over, over the years, have ended up at Cognate.

A special, independant investigator is appropriate given the lack of visibility that has been maintained for years. But they have one. We will just have to see. Whoever wrote that Phase V article better not have synthesized those accusations. The era of being able to do that under the umbrella of the first ammendment may be coming to an end.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News